AIMS: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. We hypothesized that carboplatin-etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. PATIENTS & METHODS: We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks. RESULTS: The median progression-free survival was 11 weeks (range: 8-18), while median overall survival was 18 weeks (range: 12-26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial. CONCLUSION: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer.
AIMS: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancerpatients. We hypothesized that carboplatin-etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. PATIENTS & METHODS: We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks. RESULTS: The median progression-free survival was 11 weeks (range: 8-18), while median overall survival was 18 weeks (range: 12-26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial. CONCLUSION: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer.
Entities:
Keywords:
abiraterone; carboplatin; enzalutamide; etoposide; neuroendocrine; prostate cancer
Authors: R Petrioli; G Roviello; A I Fiaschi; L Laera; Salvatora T Miano; G De Rubertis; G Barbanti; V Bianco; S Brozzetti; E Francini Journal: Med Oncol Date: 2015-01-31 Impact factor: 3.064
Authors: Giuseppe Di Lorenzo; Martina Pagliuca; Teresa Perillo; Alfonso Benincasa; Davide Bosso; Sabino De Placido; Carlo Buonerba Journal: Medicine (Baltimore) Date: 2016-04 Impact factor: 1.889
Authors: Jennifer Moritz; Thomas Bauernhofer; Sebastian Mannweiler; Tanja Langsenlehner; Karl Pummer; Nadia Dandachi; Martin Pichler Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Sarennya Pathmanandavel; Megan Crumbaker; Andrew O Yam; Andrew Nguyen; Christopher Rofe; Elizabeth Hovey; Craig Gedye; Edmond M Kwan; Christine Hauser; Arun A Azad; Peter Eu; Andrew J Martin; Anthony M Joshua; Louise Emmett Journal: J Nucl Med Date: 2021-07-29 Impact factor: 10.057